Vision and mission
To fully exploit the potential of long-acting therapeutics, a concerted investment in science, technology, regulatory pathways, clinical manufacture, and utilisation is required. Developing appropriate long-acting medicines also requires a detailed understanding of national public and patient perspectives and the acceptability of long-acting therapeutics approaches within each target patient group.
Our vision is to create a national Hub for Advanced Long-acting Therapeutics (HALo), hosted at the University of Liverpool’s CELT Global Health and partnered by leading research teams in the University of Nottingham, Queens University Belfast, and the University of Manchester. The Hub will advocate for new long-acting therapeutics development to maximise new opportunities, address key technology questions, establish long-acting therapeutics awareness across UK public, patient and clinical groups, and ensure patient involvement in appropriate future long-acting therapeutics development.
Aims and objectives
HALo will conduct world-leading physical science research that will:
- Enable the acceleration of long-acting therapeutics development
- Advocate strongly for a national strategy on long-acting therapeutics
- Create an evidence-based pathway to a national translational ecosystem to enable scale-up of industrial and academic long-acting therapeutic candidates, from pre-clinical proof-of-concept through to a UK-wide manufacturing base capable of production of Good Manufacturing Practice medicinal long-acting therapeutics products
- Create a regulatory environment to enable rapid clinical evaluation.
Mission
As the national hub, HALo will establish the UK as the world leader in long-acting medicines through an evidence-based foundation, growth of fundamental physical science understanding, accelerating long-acting proof-of-concept through patient/public/clinician involvement and engagement, creating future long-acting paradigms, and enabling translation pathways from development to the clinic.
